Therapy Areas: Diabetes
Ildong Pharmaceutical to commence IDG16177 phase one study in Germany
2 July 2021 -

Ildong Pharmaceutical, a South Korea-based pharmaceutical company, announced on Thursday that it has started a phase one study of new drug candidate IDG16177 of novel oral treatment for type 2 diabetes in Germany.

The company has received approval for the Phase one study from the German regulatory authority's Federal Institute for Drugs and Medical Devices (BfArM). The firm has started the phase one study in Berlin, based on the approval. The study is to assess the efficacy of the product in a total of 100 healthy subjects and type 2 diabetic patients. IDG16177 is to be administered to the treatment group including healthy subjects to observe its pharmacokinetics, safety, and tolerability.

The company intends to complete the Phase one study of the product by 2022.